Relmada Therapeutics
RLMD
80 hedge funds and large institutions have $298M invested in Relmada Therapeutics in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 5 closing their positions.
39,447% more call options, than puts
Call options by funds: $6.72M | Put options by funds: $17K
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
11% more funds holding
Funds holding: 72 → 80 (+8)
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
7.86% less ownership
Funds ownership: 65.19% → 57.33% (-7.9%)
24% less capital invested
Capital invested by funds: $393M → $298M (-$94.5M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$9.63M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.95M |
| 3 |
Alkeon Capital Management
New York
|
+$1.72M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$859K |
| 5 |
Millennium Management
New York
|
+$857K |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$29.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$11.3M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$10.3M |
| 4 |
TA
Tiedemann Advisors
New York
|
-$7.36M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.39M |
RLMD Hedge Fund Activity: Q4 2020 in Review
80 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2020, worth a combined $298M — down 24% from $393M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RLMD positions and 5 closed out — a net gain of 8 holders — while 26 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $9.63M. The largest seller was RA Capital Management, exiting entirely with an estimated $29.4M sold.
- 80 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2020, up from 72 in Q3 2020.
- Funds reported $298M of Relmada Therapeutics stock for Q4 2020, down 24% quarter-over-quarter.
- 13 funds opened new Relmada Therapeutics positions in Q4 2020 and 5 closed out, a net change of +8 holders.
- The largest Relmada Therapeutics buyer in Q4 2020 was BlackRock, an estimated $9.63M added.
- The largest Relmada Therapeutics seller in Q4 2020 was RA Capital Management, an estimated $29.4M sold.
Based on aggregated 13F filings for Q4 2020.